Cargando…
Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
Ontak(®), a conjugate between IL-2 and a diphtheria toxin fragment, was recently investigated in cancer clinical trials aiming to kill CD25(+) regulatory T cells (T(regs)). We found that the activity of Ontak(®) was more complex on T(regs) and conventional T cells (T(convs)) than anticipated, includ...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091105/ https://www.ncbi.nlm.nih.gov/pubmed/25050193 http://dx.doi.org/10.4161/onci.28223 |